Detailed Analysis on ANUH PHARMA LTD

 

Market Cap : 1212 Cr
Current Price (23-03-2024) : 242
Sector : Pharmaceuticals 

About :

Established in 1960, Anuh Pharma Ltd. today it is one of the largest manufacturers of Macrolides and Anti-TB products in India, besides being a major player in Anti-Bacterial, Anti-Malarial, and Corticosteroids.

Anuh Pharma Ltd., a Bulk Drugs Manufacturing Company is part of the INR 8.5 bn SK Group of Companies, which employs 2000+ people across businesses such as Manufacturing of API's, Pharma Formulations, Distribution and Logistics

Financial Metrics : 

(source : screener.in)

  • Current Price : 242.00
  • Market Cap : 1212 Cr
  • Book Value : 51.2
  • EPS : 10.83
  • Promoter Holding : 69.93 %
  • Pledged Percentage : 0.00 %
  • P/E Ratio : 22.3 (Industry PE : 34.60)
  • PEG Ratio : 1.17
  • Return on capital employed (ROCE) : 19.10 %
  • ROCE 5Yr : 16.50 %
  • Return on equity (ROE) : 14.50 %
  • ROE 5Yr : 12.90 %
  • Return on assets (ROA) : 8.76 %
  • ROA 5Yr : 7.69 %
  • Sales Growth 5Yr : 17.20 %
  • Profit Growth 5Yr : 19.00 %
  • Dividend Last Year : 2.00
  • Dividend Yield : 0.83 %
  • Debt : 8.20 Cr
  • Debt to Equity : 0.03
  • Current Assets : 292 Cr
  • Current Liabilities : 141 Cr
  • Free Cash Flow : 52.40 Cr
  • Net Cash Flow : -1.87 Cr
Please refer to this article for detailed explanation on above mentioned financial metrics
https://www.abstocks.in/2024/03/most-used-fundamentals-in-stock-market.html

Quarterly Earnings :

(source: screener.in)

The Company is consistently increasing its QOQ sales, operating profit and net profit.

Yearly Earnings :

(source : screener.in)

The company is consistently increasing its YOY sales, operating profit and net profit

Manufacturing Facility :


The manufacturing facility is located in Boisar, which is about 120 Kms away from Mumbai. The plot area is 11,400 Sq. Meters. The facility is built as per ICH - GMP Guidelines. The facility is approved by EDQM and WHO-PQ and has Eu-GMP , Local-GMP and other such certifications.
They also have an exclusive tie-up with Great Pacific Exports Pvt. Ltd. located at Navi Mumbai for manufacturing of Corticosteroids. The manufacturing facility at Navi Mumbai is also a state of the art facility built and complying to latest ICH - GMP Guidelines

Research Facility :

Spread across 10,000 square feet in Navi Mumbai, this laboratory has three sections: the Analytical Development lab, Chemical Synthesis Lab and a Pilot Plant. In addition to the facilities, the lab derives benefit from the services of excellent professionals and experienced advisors.

Products :

The company has wide range of products covering different categories
  • ERYTHROMYCIN
  • AMBROXOL HYDROCHLORIDE
  • AZITHROMYCIN
  • ERYTHROMYCIN ETHYL SUCCINATE
  • PYRAZINAMIDE
  • SULFADOXINE
  • GLICLAZIDE
  • CHLORAMPHENICOL
  • CHLORAMPHENICOL PALMITATE
  • CLOBETASOL PROPIONATE
  • ERYTHROMYCIN ESTOLATE
  • ERYTHROMYCIN PROPIONATE
  • ERYTHROMYCIN STEARATE
  • ATORVASTATIN
  • BECLOMETHASONE DIPROPIONATE
  • BETAMETHASONE ACETATE
  • BETAMETHASONE DIPROPIONATE  and many more..
Anuh Pharma Limited is one of the largest producer of Erythromycin 1st generation salts and pyrazinamide in the world. Anuh Pharma is also one of the very few to have WHO PQ for sulphadoxine and have applied WHO PQ for Pyrimethamine (Anti malaria).

The Company has over 350 customers in over 57 countries including Europe, Mexico and South Africa.

Launched Vildagliptin in Q4FY23, which is a fast-growing Type 2 Anti diabetic product.

Approved by COFEPRIS, Mexico for Erythromycin Stearate, Erythromycin Estolate, Erythromycin Ethyl Succinate.

USFDA approved Ambroxol Hydrochloride.

Company is developing 11 new products in areas of lifestyle disease like Diabetes, Hypertension, CNS, and Dermatology.

PROS :

  1. Good quarterly growth
  2. Company with no debit
  3. Annual net profits improving for last few years
  4. zero promoter pledge
  5. Improving cash flow from operation for last 2 years
  6. Good Improvement in ROCE and ROE
  7. Maintaining healthy dividend payout
CONS :
  1. Company not able to generate net cash
  2. Promoter holding has decreased in last quarter

This is not a buy/sell advice I am not SEBI registered, just providing basic details regarding this company from various sources available online, please do your own research or consult a SEBI registered investment advisor before taking any investment decision.

Thank You for reading this article if you liked this one please visit next week again for analysis on another new stock.

Comments

Post a Comment